Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced that it will
be presenting at the BioCentury/Thomson Financial 15th
Annual Future Leaders in the Biotechnology Industry Conference on
Thursday, March 27 at 1:30 pm EDT. The presentation will be webcast live
and can be accessed on the Sirtris website (www.sirtrispharma.com)
in the "Investor Relations" section. A replay will be available after
the presentation and will be archived on the company's website for two
weeks.
In January, Sirtris announced positive Phase 1b clinical trial results
with drug candidate SRT501, a proprietary formulation of resveratrol, in
patients with Type 2 Diabetes. SRT501, which targets the SIRT1 enzyme,
was found to be safe and well-tolerated, and significantly lowered
glucose at the two-hour time point in an oral glucose tolerance test
conducted as part of the 28 day Phase 1b trial of patients with Type 2
Diabetes who were naive to treatment. Sirtris' new chemical entities
(NCEs) activate SIRT1 and are chemically distinct from and 1000 times
more potent, in vitro, than resveratrol. The NCEs have been shown to
lower glucose and improve insulin sensitivity in predictive pre-clinical
models of Type 2 Diabetes. SIRT1 activators have the potential to be a
frontline therapy for Type 2 Diabetes.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that the
Company believes control the aging process. The company's headquarters
are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, the potential therapeutic
effects of SIRT1 activators including NCEs for diseases of aging, such
as Type 2 Diabetes: the progress and results of pre-clinical and
clinical studies of SIRT1 activators, such as SRT501 and Sirtris’
NCEs; and the potential of sirtuin modulators to receive regulatory
approval. These forward-looking statements about future expectations,
plans and prospects of Sirtris Pharmaceuticals involve significant
risks, uncertainties and assumptions, including risks related to the
lack of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results, the
Company's potential inability to initiate and complete pre-clinical
studies and clinical trials for its product candidates, the fact that
none of the Company's product candidates has received regulatory
approvals, the potential inability of the Company to gain market
acceptance of the Company's product candidates, and those other risks
factors that can be found in the Company's filings with the Securities
and Exchange Commission. Actual results may differ materially from those
Sirtris Pharmaceuticals contemplated by these forward-looking
statements. Sirtris Pharmaceuticals does not undertake to update any of
these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
|